DC US acted as financial advisor to Pearl Therapeutics Inc. in its definitive merger agreement to be acquired by AstraZeneca. Under the terms of the agreement, the transaction has a potential acquisition cost of up to $1.15 billion.

AstraZeneca will acquire 100% of Pearl’s shares for an initial consideration of $560 million upon completion, with $450 million to be payable if specified development and regulatory milestones are achieved and an additional $140 million payable if pre-agreed cumulative sales thresholds are exceeded.

The acquisition will bring together Pearl’s pipeline of inhaled bronchodilator products and AstraZeneca’s core capabilities in respiratory disease.